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Mechanisms by which whole chromosome instability lead to tumorigenesis have eluded the cancer research
field. In this issue of Cancer Cell, Baker et al. show that CIN induced by a defective mitotic checkpoint, under
certain genetic and tissue contexts, leads to accelerated loss of heterozygosity of a tumor suppressor gene.Chromosomal instability (CIN) resulting
from the failure to correctly segregate
sister chromatids during mitosis has
long been proposed to drive the tumori-
genic process. An abnormal chromosome
complement, or aneuploidy, is frequently
observed in tumors, and a number of
in vivo models of induced aneuploidy lead
to tumor formation or accelerate tumori-
genesis in a variety of settings (Perez de
Castro et al., 2007).
However, a simple mechanistic expla-
nation linking CIN to tumorigenesis has
eluded the cancer biology field for years.
One possibility is that CIN favors loss
of heterozygosity of tumor suppressor
genes by accelerating the missegregation
of the wild-type allele-carrying-chromo-
some. In a study in this issue of Cancer
Cell, the van Deursen lab shows that in
p53 heterozygous mice, CIN driven by
a weak mitotic checkpoint leads to the
loss of heterozygosity of the p53 locus
and acceleration of lymphomagenesis
(Baker et al., 2009).
Defects in the mitotic checkpoint, a
molecular mechanism that ensures cor-
rect chromosome segregation during
mitosis, have been causally implicated in
CIN by a number of different studies.
Both partial loss of function of key mitotic
checkpoint genes (e.g., bub1, bubR1,
cenpE, mad2, mad1) as well as overex-
pression of some of these gene products
(e.g., Mad2, Hec1) lead to CIN and, in
many cases, to spontaneous tumor onset
(Perez de Castro et al., 2007). In the
current study, Baker et al. focus on
whether reduced Bub1 levels, which
were known to generate aneuploidy (Je-
ganathan et al., 2007), could accelerate
loss of heterozygosity of known tumorsuppressor genes and, by so doing,
accelerate tumor onset. While their results
clearly show that LOH can be accelerated
by CIN in certain cases, as discussed
below, they also underscore the impor-
tance of context in subsequent tumor
formation.
p53 heterozygous animals typically
develop sarcomas and a low frequency
of thymic lymphomas (Jacks et al.,
1994). Mice with reduced levels of Bub1
(bub1/H) showed a greatly accelerated
incidence of thymic lymphomas in the
context of p53 heterozygosity, and lym-
phoma cells from these animals showed
numerical and structural chromosome
abnormalities. Moreover, all lymphomas
analyzed had lost the remaining wild-
type copy of p53. Remarkably, tumor cells
had also duplicated the mutant allele as
seen by spectral karyotyping and allele-
specific PCR. This duplication is likely
a result of mis-segregation or mitotic
nondisjunction given the presence of
bub1/H induced CIN and the fact that
informative SNP markers are also dupli-
cated distal to the p53 locus, ruling out
mitotic recombination and gene con-
version.
The observation of loss of heterozy-
gosity of the wild-type tumor suppressor
allele and duplication of the mutant one
was also seen with bub1 hypomorphism
in the context of the APCmin/+ model of
colon adenocarcinoma. APCmin/+ animals
normally develop small intestinal ade-
nomas at complete penetrance but
develop colon adenocarcinomas at low
frequency (Luongo et al., 1994). When
crossed to bub1/H animals, colon tumor
incidence was increased 3-fold. In all
cases analyzed, allele-specific PCR con-Cancer Cell 16,firmed loss of heterozygosity of the APC
wild-type allele and FISH showed dupli-
cation of the mutant one. Unlike with the
p53 lymphomas, however, whether the
duplication of the mutant APCmin allele
was a result of chromosome duplication,
mitotic recombination or gene conversion
was not established given the lack of
informative SNP markers in the studied
strain.
LOH and duplication of the mutant
chromosome in the context of mitotic
CIN raises the question of whether this
mechanism is specific for mitotic check-
point defects. Apparently not. Studies by
others have already shown that in p53+/
animals, tumors induced by irradiation
(Tanaka et al., 2002), as well as sponta-
neous tumors (A. Balmain, personal
communication), also lose the wild-type
chromosome and duplicate the mutant
one. Hence, the CIN imparted by bub1
hypomorphism is not introducing a new
mechanism for tumor progression but
accelerating one that is already com-
monly seen in this setting.
In contrast to the observations seen
with p53 and APC, bub1/H failed to
accelerate the appearance of pituitary
adenomas in Rb+/ animals and did not
significantly affect prostate lesions in the
context of PTEN heterozygosity. In fact,
in the PTEN+/ setting, though bub1
hypomorphism had no effect on the inci-
dence of advanced stage IV prostatic
intraepithelial neoplasia (PIN IV), there
was a reduction in the number of less
aggressive PIN II and PIN III lesions. The
observations in theRb and PTEN systems
suggest that the role of CIN in acceler-
ating tumorigenesis is very much context
dependent. In fact, even in the p53December 8, 2009 ª2009 Elsevier Inc. 451
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Previewsheterozygous animals, which normally
develop sarcomas at a higher incidence
than lymphomas, bub1 partial loss of
function had no effect on sarcoma inci-
dence. Though APCmin/+ colon tumor
incidence was similarly increased in the
bub1+/ setting, no change was seen in
the incidence of small intestinal tumors,
which are also seen in this strain. The
mechanistic basis for this context depen-
dence will require further studies. Tech-
nologies to carefully measure rates of
aneuploidy and LOH in early neoplastic
lesions will undoubtedly aid in this
analysis.
Previous studies have already sug-
gested that CIN might, in some contexts,
act as a tumor suppressor (Garcia-
Higuera et al., 2008; Rao et al., 2005;
Weaver et al., 2007). Baker et al.’s study
reinforces the notion that whether CIN
favors or prevents tumor formation and
progression is very much subject to the
setting under which it occurs. Certain
cell types may be particularly sensitive
to abnormal chromosome complements
and be eliminated in early lesions.
Whether non-cell-autonomous effects
are at play in such suppression has not
yet been analyzed. Aneuploidy in cells
of the tumor microenvironment, for
example, may contribute in some tissue
types to tumor suppression. ConditionalProliferation and T
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The finding that, in the setting of p53 or
APCmin heterozygosity, the mutant allele
is similarly duplicated strongly suggests
that there is selective pressure tomaintain
two copies of the chromosome harboring
the tumor suppressor that undergoes
LOH. Haploinsufficiency of genes on this
chromosome likely decreases the fitness
of cells that have undergone such a loss,
and these cells are rapidly outcompeted
in the population.
The results presented in this issue by
Baker et al. provide the first evidence for
a potential mechanism by which CIN can
lead to tumorigenesis by linking aneu-
ploidy to loss of heterozygosity of tumor
suppressor genes. As so often happens
with important advances in cancer
biology, more questions are now raised.
Could CIN favor the duplication of chro-
mosomes harboring oncogenic mutations
at the same time as it accelerates the loss
of tumor suppressors? Does CIN occur
prior to the loss of tumor suppressors
and is it generally present in early preneo-
plastic lesions as one might predict from
the current analysis? Does such amecha-
nism of mutant chromosome retention
occur in human cancers?
Nonetheless, this study uncovers an
important mechanistic insight into howumor Suppression
sive for Eph Rece
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ia San Diego, La Jolla, CA 92093, USA
troversial regulators of cancer devel
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pletely understood how these receptors
affect cancer progression. Opposite
tumor-promoting and tumor-suppressing
9 Elsevier Inc.LOH is accelerated by defects in the
mitotic checkpoint pathway and paves
the way for a deeper understanding of
the role of CIN in cancer initiation and
progression.
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